Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00438360
Status:
COMPLETED
Last Update Posted:
2011-08-09
First Post:
2007-02-21
Brief Title:
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 24-week Double-blind Randomized Placebo-controlled Multicenter Study to Evaluate the Effectiveness of Cyclosporine 25 mgkgDay Bid Twice a Week on Reducing Relapse Rate in Maintenance Patients With Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the efficacy of cyclosporine at 2 5 mgkgday bid ie bis in a day when administered twice a week compared to continuous administration in patients with chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None